2023 - Research.com Medicine in Taiwan Leader Award
2022 - Research.com Medicine in Taiwan Leader Award
2008 - Fellow, The World Academy of Sciences
His primary scientific interests are in Lung cancer, Pathology, Internal medicine, Cancer research and Metastasis. Pan-Chyr Yang has included themes like Cancer, Adenocarcinoma, Respiratory disease, Carcinoma and Macrophage in his Lung cancer study. Pan-Chyr Yang has researched Pathology in several fields, including Inflammation and Gene expression.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Surgery and Oncology. His work deals with themes such as Cell culture, microRNA, Immunology and Epidermal growth factor receptor, which intersect with Cancer research. His studies deal with areas such as Cell growth, Cancer cell, Carcinogenesis, Microarray and Tumor progression as well as Metastasis.
Pan-Chyr Yang mainly investigates Internal medicine, Lung cancer, Cancer research, Cancer and Oncology. As part of one scientific family, Pan-Chyr Yang deals mainly with the area of Internal medicine, narrowing it down to issues related to the Surgery, and often Respiratory disease. His research in Lung cancer intersects with topics in Carcinoma, Epidermal growth factor receptor and Adenocarcinoma.
His study looks at the relationship between Cancer research and topics such as Metastasis, which overlap with Slug. Pan-Chyr Yang does research in Cancer, focusing on Cancer stem cell specifically. Pan-Chyr Yang studies Pathology, namely Immunohistochemistry.
Pan-Chyr Yang focuses on Cancer research, Lung cancer, Internal medicine, Oncology and Adenocarcinoma. His Cancer research research integrates issues from Cell, Cancer cell, Apoptosis, Metastasis and Immunotherapy. His Metastasis course of study focuses on Slug and Epithelial–mesenchymal transition, Hypoxia, Death-associated protein 6 and HDAC1.
His Lung cancer research includes themes of Cancer, Epidermal growth factor receptor and Tyrosine-kinase inhibitor. His Oncology research is multidisciplinary, incorporating elements of Reverse transcription polymerase chain reaction, PI3K/AKT/mTOR pathway, Disease and Chemotherapy. His Adenocarcinoma study combines topics in areas such as Carcinogenesis, Pathology, Lung, Gene silencing and Single-nucleotide polymorphism.
His primary areas of study are Cancer research, Internal medicine, Lung cancer, Oncology and Adenocarcinoma. His Cancer research study incorporates themes from Epidermal growth factor receptor, Apoptosis, Immunology, Metastasis and Immunotherapy. His Metastasis research incorporates themes from Slug and Cancer cell.
His work carried out in the field of Internal medicine brings together such families of science as Mutation, Reverse transcription polymerase chain reaction and Psychological intervention. The Gefitinib research Pan-Chyr Yang does as part of his general Lung cancer study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science. His Adenocarcinoma research incorporates elements of Disease, Pathology, Lung, Tumor progression and Single-nucleotide polymorphism.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson.
Journal of Thoracic Oncology (2011)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean;Cameron Brennan;Jin-Yuan Shih;Gregory Riely.
Proceedings of the National Academy of Sciences of the United States of America (2007)
A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
Yuankai Shi;Joseph Siu-Kie Au;Sumitra Thongprasert;Sankar Srinivasan.
Journal of Thoracic Oncology (2014)
A five-gene signature and clinical outcome in non-small-cell lung cancer.
Hsuan Yu Chen;Sung Liang Yu;Chun Houh Chen;Gee Chen Chang.
The New England Journal of Medicine (2007)
MicroRNA Signature Predicts Survival and Relapse in Lung Cancer
Sung Liang Yu;Hsuan Yu Chen;Hsuan Yu Chen;Gee Chen Chang;Chih Yi Chen.
Cancer Cell (2008)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary.
William D. Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G. Nicholson.
Proceedings of the American Thoracic Society (2011)
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
Kang-Yi Su;Hsuan-Yu Chen;Ker-Chau Li;Ming-Liang Kuo.
Journal of Clinical Oncology (2012)
Value of sonography in determining the nature of pleural effusion: analysis of 320 cases.
Pan-Chyr Yang;Kwen-Tay Luh;Dun-Bing Chang;Huey-Dong Wu.
American Journal of Roentgenology (1992)
Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications.
Jin-Chuan Sheu;Juei-Low Sung;Ding-Shinn Chen;Pei-Ming Yang.
p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug.
Shu Ping Wang;Wen Lung Wang;Yih Leong Chang;Chen Tu Wu.
Nature Cell Biology (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: